CPA
LLY icon

Capital Performance Advisors’s Eli Lilly LLY Stock Holding History

Capital Performance Advisors’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Sell
2,314
-1,318
-36% -$1.35M 0.18% 60
2026
Q1 		$3.34M Buy
3,632
+434
+14% +$440K 0.22% 55
2025
Q4 		$3.44M Buy
3,198
+452
+16% +$432K 0.24% 53
2025
Q3 		$2.1M Buy
2,746
+494
+22% +$368K 0.35% 42
2025
Q2 		$1.76M Sell
2,252
-437
-16% -$340K 0.34% 46
2025
Q1 		$2.22M Buy
2,689
+2,100
+357% +$1.75M 0.49% 35
2024
Q4 		$455K Sell
589
-171
-23% -$142K 0.15% 62
2024
Q3 		$673K Buy
760
+300
+65% +$270K 0.2% 42
2024
Q2 		$417K Buy
460
+36
+8% +$28.8K 0.16% 53
2024
Q1 		$330K Buy
424
+51
+14% +$36.3K 0.13% 56
2023
Q4 		$217K Buy
+373
New +$218K 0.09% 66

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Performance Advisors's LLY Position: Q2 2026 in Review

Capital Performance Advisors reduced its Eli Lilly (LLY) stake by 36% in Q2 2026, selling an estimated $1.35M and leaving 2,314 shares worth $2.78M. The position accounts for 0.18% of the portfolio, ranked #60.

Capital Performance Advisors first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.44M in Q4 2025. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Capital Performance Advisors held 2,314 shares of Eli Lilly worth $2.78M as of Q2 2026.
  • Capital Performance Advisors sold 1,318 Eli Lilly shares in Q2 2026, an estimated $1.35M.
  • Eli Lilly made up 0.18% of Capital Performance Advisors's portfolio in Q2 2026, its #60 holding.
  • Capital Performance Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • Capital Performance Advisors's Eli Lilly position peaked at $3.44M in Q4 2025.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.